Biotech M&A Activity through September 13th - Rate Cut the Tailwind Sector Has Been Waiting For

Week Ending September 13th, 2024:

• Biotech: 12 Transactions (3 IPOs, 6 Follow-Ons, 2 PIPEs, and 1 RD) totaling just under $3 Billion

• Medtech: No Current Week Transactions

2024 YTD:

• 212 Biotech transactions totaling just over $37 Billion v. 2023 YTD: 125 Biotech transactions totaling just under $18 Billion

• 8 Medtech transactions totaling just over $1 Billion v. 2023 YTD: 6 Medtech transactions totaling just over $400 Million

Private Transactions:

• Biotech: 195 US Transactions/ 76 European Transactions

• Medtech: 128 US Transactions / 43 European Transactions

September M&A Deals:

• Organon acquired Dermavant for $175M

August M&A Deals:

• Crown Laboratories acquired Revance for $924M or $6.66/share

• Pharmacosmos acquired G1 Therapeutics for $405M or $7.15/share

• Otsuka Pharmaceutical acquired Jnana Therapeutics for $800M